Media OutReach
Bora 3Q25 Delivers Renewed Profitability as Efficiency and Scale Improves
Strategic realignment powering Bora’s dual-engine businesses model
HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third quarter of 2025.
Quarterly Business and Financial Highlights
- Company reported quarterly basic EPS of NT$5.09, with a loss per share of NT$1.49 from discontinued operations. Operating income reached NT$1,063 million and net income for continued operations came in at NT$822 million, resulting in quarterly EBITDA of NT$1,283 million, well on track to reclaim 2023 core P&L indicators.
- By the end of 3Q25, Bora’s operational integration and strategic streamlining efforts have been fully executed, meeting all targeted objectives. This milestone has led to a record-high CDMO business profitability, clear evidence that Bora’s dual-engine model is now entering its next phase of balanced but scalable growth.
- Fueled by expanded capacity and the addition of new dosage forms, Bora’s CDMO business grew 56.5% year-to-date through 3Q25, reaching over NT$7.3 billion and returning to a sequential growth trajectory.
- Pharma sales revenues fluctuated as legacy inventory phased out, and new products are still awaiting approvals. Generics portfolio competitiveness remains a key focus area in the near term. Led by Vigafyde, Bora’s rare disease portfolio continued to gain impressive market share with the vigabatrin franchise across three dosage forms continues. The Company targets to file its next specialty pharma product by year end to accelerate the rare neurology disease business. The Company also targets to market branded Deflazacort tablets by 2025 year end as a new driver for the business.
- The Company expects NTD to remain in the range of NTD 30-31 per USD for its operational planning.
- Share capital increased 19.99% during the quarter from stock dividend distribution, employee stock option exercise and convertible bond conversions.
- The Board approved Level-1 ADR issuance with each ADR share corresponding to 1/5 common share and total ADR issuance <10% of outstanding shares to enhanced market trust and investor service.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “Bora executed a record level of post-merger CAPEX investment in 2025 and we are progressing in line with our strategic plan. We have expanded our Maryland aseptic fill/finish capacity by approximately 10% while solid and liquid dosage capacity in Minneapolis and Mississauga grew around 3%. The investments allowed Bora to increase our operational efficiency and increase revenue per headcount in the CDMO business by ~30% during the quarter compared to beginning of the year.
The CDMO backlog rose to US$296 million, driven by 27 new contracts and over 20 new molecules year-to-date, providing solid visibility into 2026 with 72% commercialized projects. Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio, while paving the way for selective in-house manufacturing of specialty assets in the U.S.
As we look ahead, Bora is entering a phase of disciplined expansion and broader global recognition. Across our CDMO facilities in Asia and North America, we continue to actively navigate tariff and geopolitical challenges and turn them into new opportunities, strengthening supply chain resilience, and deepening collaboration with multinational partners.
On the pharma sales side, we continue to shed legacy low margin generics, increase our cashflow, and focus on our high-value generics pipeline, with certain PIV opportunities progressing to maturity in 2026. We remain dedicated on enhancing portfolio quality and increasing our Branded assets through selective specialty drugs, in order to build a more predictable and margin-accretive revenue base that mitigates product commoditization and price degredation.
In parallel, we are expanding our capital-market reach into the United States through the OTCQX Level-1 ADR program. We believe the Bora ADR will improve access and transparency for global institutional investors, while enabling overseas employees to participate in Bora’s growth. With no dilution and increasing visibility, we are laying the foundation for a stronger and more global 2026, defined by scaled growth, operational synergies, and increasing investor confidence.
3Q2025 Operational Achievements & Full Year Outlook
Global CDMO Operations
Global CDMO Operations (excluding intercompany orders from Upsher-Smith) revenues arrived at NT$1.78 billion in the third quarter and back to the sequential growth zone, representing approximately 37.13% of total revenue. A total of 418 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 33%. Year-to-date, CDMO revenues grew 18.98% over last year and reached NT$5.27 billion. Bora continues to execute on expanding this customer base to enhance business visibility and stability.
- As the Company ramps up its Maple Grove site, the momentum for U.S. manufacturing has been encouraging. Several clinical-stage clients are now transitioning into long-term strategic partnerships, with project scale and client size both increasing. Maple Grove is well positioned to be the Center of Excellence for scale-up and U.S. supply-chain integration for Bora.
- Large molecule CDMO operation revenues saw nearly 50% increase over the previous quarter, driven by one new ADC client and several change orders in addition to Cipla’s own labeled product launch under the collaboration agreement. Positioned as a one-stop CDMO platform alongside Bora Pharmaceuticals, Bora Biologics is now fully accelerating its CDMO operations
Pharma Sales Operations
Pharma Sales Operations in the third quarter reached a revenue of NT$3.02 billion, down 6.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 62.83% of total revenues.
- Discontinued loss per share (from the closure of the Plymouth production area) reflected the clearance sale of higher-cost inventories from Upsher-Smith’s legacy generics and internal supply transfer delayed by regulatory hurdles. These inventory clearance sales are now nearing completion. The greater-than-expected pricing pressure across our low margin generics reinforces the need to accelerate Bora’s transition toward higher-value and Branded specialty pharma products.
- The Vigabatrin franchise market share expansion continues with the “total patient” indicator seeing breakthrough in October.
- Bora continues to focus on DEE (Developmental and Epileptic Encephalopathies), where legacy compounds fail to meet significant unmet needs. The market is poised for new NCE entrants, expanding the addressable opportunity to roughly US$10 billion over the next 3–5 years. Bora aims to capture this growth through a Ready-to-Use 505(b)(2) pipeline and branded generics.
Recent Investor Conference
Bora will host an English online earnings call at 8:00 p.m. Taiwan time on Nov. 13th, 2025, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:30 p.m. on Nov. 14th, 2025. Both events will cover the company’s Q3’25 financial and business results and outlook.
English Online Earnings Presentation Link: https://events.q4inc.com/attendee/477519089
Bora will participate in the JP Morgan Healthcare Conference in January in San Francisco. For 1:1 meetings with management, please contact your JP Morgan representative.
Bora 2025 Earnings Schedule
Q4 2025: Expected in the 2nd week of March 2026
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, visit www.bora-corp.com.
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Media OutReach
Luxury Hair Clinic Sheer Reprime Marks 8th Anniversary with a Flagship Expansion into Hong Kong’s Prestigious Wellington Street
Luxury hair and scalp rejuvenation pioneer Sheer Reprime invests nearly HK$10 million to deploy next-generation, FDA and CE-certified hair restoration and scalp rejuvenation technologies.
HONG KONG SAR – Media OutReach Newswire – 8 June 2026 – Celebrating eight years of clinical excellence, premier hair and scalp rejuvenation brand Sheer Reprime today announced the grand opening of its ultra-luxury flagship center on Wellington Street, Central. Representing a strategic investment of nearly HKD10 million, the expansive facility positions Sheer Reprime at the epicenter of Hong Kong’s elite financial and cultural district. This expansion marks a new era of medical-grade, advanced hair restoration and scalp rejuvenation.
Located at 50 Wellington Street, adjacent to the iconic Yung Kee restaurant, the near-full-floor flagship features private treatment suites engineered for maximum comfort and discretion. The venue is optimized for busy and successful individuals, stars and celebrities seeking world-class clinical trichology with exceptional hospitality.
Bridging Follicle Biology and Biophotonics
Sheer Reprime’s expansion directly addresses a surging global market demand for scientifically backed hair-loss solutions, particularly as stress and lifestyle factors accelerate the onset of premature thinning among younger demographics.
“Our expansion into the heart of Central marks a watershed moment for Sheer Reprime,” said a Brand Spokesperson. “The modern consumer demands rigorous, evidence-based hair and scalp treatments. Sheer Reprime is built at the intersection of Follicle Biology and Biophotonics. Our multi-million-dollar investment into an advanced clinical instrumentation allows us to optimize the scalp microenvironment at a cellular level, far surpassing the limitations of older generation treatments.”
Internal clinical metrics validate the brand’s scientific approach. In a recent study tracking 100 urban professionals over a 12-week regimen of Sheer Reprime’s laser hair rejuvenation therapy, participants demonstrated an average increase of 22% in hair shaft thickness and an 18% increase in active follicular density.
Departing from standard industry practices focused merely on surface-level scalp cleansing, Sheer Reprime introduces its proprietary Connotation Therapy. This multi-modality framework combines technologies which have received FDA, Medical CE, and EU MDR (Medical Device Regulation) certifications. Amongst them SLD LLLT hair loss treatment, which delivers biophotonic laser energy 3–5mm beneath the scalp surface to revive the follicular base. Winback Tecar Therapy and 500kHZ cellular radio frequency, which utilizes deep thermal energy to enhance localized microcirculation across the head, neck, and shoulders, maximizing nutrient and oxygen delivery to the hair bulb while flushing out metabolic waste and DHT (dihydrotestosterone).
The launch of Sheer Reprime’s Wellington Street flagship redefines the luxury trichology landscape in Hong Kong, merging clinically proven regenerative technologies with an unparalleled bespoke experience.
Hashtag: #sheerreprime #煥光活髮
The issuer is solely responsible for the content of this announcement.
About Sheer Reprime
Sheer Reprime is a premier scientific hair and scalp rejuvenation brand. By fusing Follicle Biology with Biophotonics, the brand transcends the boundaries of traditional hair care. Operating its multi-million-dollar flagship in Central, Sheer Reprime deploys FDA and CE-certified medical-grade technologies to lead the global industry into the era of cellular hair restoration. For more information, visit:
http://www.reprime.hk
Media OutReach
Trransfer Technologies And LINE GO Partner To Expand Enterprise Ground Transportation Across Taiwan And Global Markets
Partnership combines LINE GO’s MaaS ecosystem platform with Trransfer Technologies’ global B2B ground transportation platform to serve Taiwan’s growing outbound business travel demand
SINGAPORE – Media OutReach Newswire – 8 June 2026 – Trransfer Technologies, a global B2B ground transportation platform serving corporate travel managers, private aviation firms, banks, luxury concierge services and enterprise customers to fulfill across more than 80 destinations worldwide, announced the official launch of its strategic partnership with LINE GO, Taiwan’s premier MaaS (Mobility as a Service) ecosystem platform. Officially commencing today, the partnership follows a successful one-month operational pilot since May 11, 2026, and is designed to unlock new enterprise demand in Taiwan while creating a scalable outbound travel solution for Taiwanese companies, multinational corporations and business travelers.
Taiwan’s outbound travel market reached 18.94 million departures in 2025, a 12.43 percent increase from 2024 and a new historical high. This upward trajectory underscores a compelling opportunity for enterprise-focused mobility providers to capture demand from corporations and business travelers who require seamless, reliable ground transportation solutions across global destinations.
A Partnership Built on Complementary Strengths
Trransfer Technologies will bring international corporate and enterprise travel demand into Taiwan, with LINE GO providing local fulfillment through its established mobility network, operational capabilities and deep integration within the LINE ecosystem. LINE GO’s MaaS platform aggregates seven mobility services including taxi-hailing, car rentals, airport shuttles, designated driver services, scooter sharing, private car charters and an EV charging network, giving enterprise clients a comprehensive local mobility experience upon arrival in Taiwan.
Looking ahead, both companies will extend their collaboration to serve the outbound travel needs of Taiwan-based enterprises, leveraging Trransfer Technologies’ global destination network across more than 80 destinations worldwide. This positions both companies to become the preferred mobility partner for Taiwanese businesses and multinationals requiring end-to-end ground transportation coordination across borders.
Targeting Taiwan’s Enterprise Traveler Segment
The partnership specifically targets multinational corporations, corporate travel managers, enterprise clients and high-frequency business travelers. As Taiwan’s outbound travel continues its upward trajectory, enterprises increasingly need partners who understand both local logistics and the complexity of global coordination.
“This partnership creates immediate strategic value for both companies. LINE GO brings market-leading mobility technology and operational insights, while Trransfer Technologies contributes the global platform, enterprise workflows and international fulfillment network. Together, we are building a scalable outbound mobility solution for Taiwanese enterprises traveling globally.”
Michael Chiay, Chief Executive Officer, Trransfer Technologies
“This collaboration marks a transformative milestone in LINE GO’s journey. We are proud to offer our partners a one-stop solution that delivers on our promise to make every journey smarter, safer, and more efficient.”
Isaac Lin, Managing Director, LINE GO
Hashtag: #TrransferTechnologies #MaaS #BusinessTravel #CorporateTravel #TravelTech #GlobalMobility #TrransferTechnologies #LineGo #EnterpriseTravel #SmartMobility #concierge
The issuer is solely responsible for the content of this announcement.
About Trransfer Technologies
Trransfer Technologies is a global B2B ground transportation platform connecting corporate travel managers, private aviation firms, banks, luxury concierge services and enterprise customers with local ground transportation operators to fulfill across more than 80 destinations worldwide. The company provides a unified platform designed to simplify business travel mobility, improve supplier coordination and support seamless ground transportation fulfillment across markets.
For more information, please visit www.trransfer.com.
About LINE GO
LINE GO is Taiwan’s premier MaaS platform offering taxi-hailing, car rentals, airport shuttles, designated driver services, scooter sharing, private car charters and an EV charging network, all within the LINE ecosystem. In 2025, LINE GO achieved dual ISO 27001 and ISO 27701 certifications, underscoring its commitment to world-class information security and data privacy.
Media OutReach
Sun Group debuts at SITF 2026 with exclusive Phu Quoc flight deals and a fresh vision for Vietnam tourism
A special highlight is Sun Group’s unveiling of its new development vision for Phu Quoc in the lead‑up to APEC 2027, presented directly to Korean partners and visitors.
From the first day of the fair, Sun Group’s booth has welcomed a steady stream of visitors. Throughout the four-day event, the booth has organized B2B and B2C networking activities, customer consultations, and introductions to tourism, resort, and aviation products. Interactive programs, including mini-games, souvenir giveaways, and tailored offers for the Korean market, have kept the atmosphere lively for hours, with a continuous flow of engaged visitors.
During SITF (June 4–7), travelers have the opportunity to receive a 20% discount on the base fare when booking Sun PhuQuoc Airways tickets via the airline’s website or app. The offer applies to the Korean market for one‑way or round‑trip journeys from Korea to Phu Quoc. Limited to 200 Economy Class discount codes, it is valid for flights from June 15 to October 24, 2026 (excluding peak periods as defined by the airline).
Visitors also have the chance to win attractive prizes through booth activities, including free round‑trip air tickets on the Seoul–Phu Quoc route (ICN–PQC) and resort vouchers at hotels within Sun Group’s ecosystem.
By combining destination promotion with airline incentives, Sun Group aims to further encourage South Korean tourists to choose Vietnam for their upcoming holidays, especially Phu Quoc, which is entering a new era of large‑scale investments in projects, products, and experiences all aimed at APEC 2027.
Hashtag: #SunGroup
The issuer is solely responsible for the content of this announcement.
About Sun Group
Vietnam’s leading private economic group, Sun Group operates an integrated ecosystem spanning tourism, entertainment, hospitality, real estate, infrastructure, and aviation. Guided by the mission “Enhancing the beauty of the lands,” the Group shapes iconic destinations nationwide through its Sun World entertainment brand. In the aviation sector, Sun Group develops a hub-and-spoke model anchored by Phu Quoc, driven by strategic airport investments and Sun PhuQuoc Airways.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn
